StimLabs Receives the US FDA’s 510(k) Clearance for Corplex P as a Management Therapy for Acute and Chronic Wounds
Shots:
- The company received the US FDA’s 510(k) clearance for its human umbilical cord-derived Corplex P. The company had earlier launched an intact placental membrane allograft in 2016
- The clearance was granted based on the results from the clinical study depicting the safety and effectiveness of Corplex P through testing, compliance with pre-market submission requirements
- Corplex P is a medical device derived from the human umbilical cord extracellular matrix (ECM) approved and indicated for the management of acute and chronic wounds
Ref: StimLabs | Image: StimLabs
Related News:- SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
